Najah Sampson

Najah Sampson is President of Pfizer Canada, a position she has held since May 2022. 

In her 20+ year career at Pfizer, Ms. Sampson has held commercial leadership positions at all levels in the organization.  Ms. Sampson served as Vice President and Chief of Staff to Pfizer’s Chairman and CEO, overseeing operations to advance enterprise priorities, supporting the Executive Leadership Team and Board of Directors, and coordinating with leaders across the organization to enable a strong corporate culture.  

Over the years, she has led several global teams within the Oncology business, establishing global launch and lifecycle plans for portfolios of early development and late-stage assets across hematologic, breast, and lung cancers. Prior to her appointment as Pfizer Canada President, Ms. Sampson was Vice President, Global Genitourinary Franchise Lead for Pfizer Oncology. She was responsible for ensuring global strategy development and implementation for an industry-leading portfolio of innovative brands and pipeline medicines in prostate, bladder and kidney cancers and the Oncology biosimilar portfolio. 

Ms. Sampson began her career with Pfizer in the US organization managing a portfolio of quality improvement programs and enabling engagement strategies for managed care and institutional customers.   

She is a member of the Board of Directors of Innovative Medicines Canada, a member of BIOTECanada and a member of the Business Council of Canada. 

Ms. Sampson holds a BS and an MBA from Florida A&M University. Outside of work, Ms. Sampson an active supporter of healthcare charities and organizations. She is an avid traveler and enjoys time outdoors with her husband and young daughter.